RxDoctor Payments Data

Natalie King-Selario, DO

Family Medicine · Bridgeport, WVNPI 1225214240

Payments from drug & device makers

$4,071in general payments, 2019–2025

Across 237 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$973
  • AstraZeneca$350
  • Amarin Pharma, Inc.$350
  • Novo Nordisk$345
  • Amgen$288
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$228
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$1754%
  • Food & beverage$3,81694%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,071 in reported general payments places this provider in the 85th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$158,861
Medicare patients
700
Services billed
4,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide68$74,052
JardianceEmpagliflozin51$69,275
FarxigaDapagliflozin Propanediol29$29,234
VascepaIcosapent Ethyl60$28,238
EliquisApixaban20$22,270
JanuviaSitagliptin Phosphate20$21,656
MounjaroTirzepatide13$13,160
Tiotropium Bromide18$9,462
Icosapent Ethyl26$8,445
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$5,524
Combivent RespimatIpratropium/Albuterol Sulfate11$5,063
Varenicline Tartrate19$3,323
Levothyroxine Sodium262$3,035
Atorvastatin Calcium368$2,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$219$87,21181 claims
Boehringer IngelheimJardiance, Combivent Respimat$166$74,33962 claims
AstraZenecaFarxiga$350$29,23429 claims
PfizerEliquis$178$22,27020 claims
AbbVieSynthroid$973$1,03420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Bridgeport

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →